Meeting
2023 ASCO Genitourinary Cancers Symposium
CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
Authors
Laurence Albiges
Medical Oncology, Gustave Roussy, Université Paris Saclay, Paris, France
Laurence Albiges , Thomas Powles , Anand Sharma , Balaji Venugopal , Jens Bedke , Pascale Dutailly , Bryan Qvick , Lidia Martin-Couce , Valérie Perrot , Viktor Grünwald
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03945773
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 606)
DOI
10.1200/JCO.2023.41.6_suppl.606
Abstract #
606
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
First Author: Geoffrey Thomas Gibney
Poster
2023 ASCO Genitourinary Cancers Symposium
CARINA interim analysis: A non-interventional study of real-world treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy.
First Author: Paul D. Nathan
Poster
2020 Genitourinary Cancers Symposium
CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs).
First Author: Laurence Albiges
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
First Author: Pratik Rane